NM-404

Brain Metastases

University of Wisconsin, MadisonSmall moleculeDormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

103 Active assets in the Brain Metastases cohort.

Asset / Sponsor	Phase	Rating
TRASTUZUMAB Iambic Therapeutics, Inc	Phase 4	BB
Zorifertinib Alpha Biopharma (Jiangsu) Co., Ltd.	Phase 2/3	BB
Trastuzumab Deruxtecan Baptist Health South Florida	Phase 4	BB
Icotinib Betta Pharmaceuticals Co., Ltd.	Phase 3	BB
Copper Cu 64-DOTA-Trastuzumab City of Hope Medical Center	Phase 4	BB

View all 50 →

Same molecule, other indications

NM-404 is also rated in:

non-small cell lung carcinomaDormant

CC

Indicative ·

40 / 100

Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck CancerDormant

D

Indicative ·

30 / 100

glioblastomaDormant

D

Indicative ·

28 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.